||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Silence Therapeutics Share Discussion Threads
Showing 49951 to 49972 of 49975 messages
|Thanks for this Waterloo but you could actually look at this as a positive for SLN in that the failure of their delivery mechanism just highlights the proven track record safety profile of SLN's delivery mechanisms.|
|'Silence has confirmed the potential of its delivery platform for in vivo gene editing'...
looks like a leap forward for Silence. Certainly very good news indeed|
|A bit technical for me, but that RNS sounds like good news...|
|I don't think I'll be running just yet.
"Safety problems have not shown up to date in the company's other RNAi drugs, which are all delivered into patients differently from revusiran, Maraganore said. He added that he still expects to have three drugs approved and on the market by 2020."
... but certainly a reminder of the other side of the coin for biotech from the SUMM experience.|
|Decent volume today. Are we getting a bit of the SUMM slipstream?|
|Well that's why we buy into biotech I suppose - hoping to get a new treatment through to commercialisation or have someone with deep pockets buy in to help progress a potential treatment. SLN's turn may come...
In the meantime it can't do any harm to have a reminder of what can happen.|
|Looking at todays announcement from SUMM, doesn't it just make you envious. Surely our turn will come!|
|Canaccord Genuity today reaffirms its buy investment rating on Silence Therapeutics PLC (LON:SLN) and raised its price target to 249p (from 233p).|
|I asked Ali M about the risk of costly legal battles at the AGM given the annual report statement that "the Company has received advice from three separate law firms indicating that the issued claims potentially capture other development stage siRNA candidates" as well as the disagreement over the milestone payment with Quark.
I got the impression from him that the "legal opinions" statement wasn't as bad as it sounded (to me) and that this was largely a due diligence move to strengthen the case for seeking licensing fees as a result of the new patent granted. I can't remember the detail but I think perhaps the reason for "several" opinions is that there are several drugs they are hoping to bring within scope of their patents.
And I am pleased to see from today's statement that the Quark issue has gone to arbitration rather than litigation.|
|Long wavelength is right. Never liked Quark (and SLN seem to have a few issues as well) and talk of favourable legal opinions says to me they will have some court cases to fight. Nothing substantial in trials. I'll leave you with your deep base resonance.|
|It's a fairly long wavelength business though, isn't it? I don't think we should expect to see dramatic new developments every few months. Even so, the section on licensing looks pretty positive to me:
"In December 2015, the Company had a further patent (9,222,092) granted in the US, which substantially broadens its position in modified siRNA molecules and we continue to seek additional granted claims through a program of continuation filings.
In the past six months Silence has obtained several favourable legal opinions indicating that multiple siRNA based drugs currently in clinical development potentially fall within its issued claims. Subsequently, the Company has invited the relevant companies to enter licensing negotiations.
The strengthened position around AtuRNAi® makes this asset an even more significant value driver, comprising existing licensee Quark’s clinical progress, ongoing negotiations and potential additional licences."|
|Seems like very little progress on any fronts since I last looked a year ago.|
|Not in anymore, but has that much changed when aut027 was/is the companies lead and main trial? Never liked it when they went for combo.|
|I've a feeling that it will be announced that atu027 has been discontinued but kind of already in the price, I suspect. Hopefully, other developments will more than counterbalance this.|
|What chance things get a bit busier tomorrow with the interims?|
|Nice to see another bounce today, this time on what looks like low volume. Not at all clear to me why it's bouncing though...|
|Are we expecting any news now the price has picked up together with the volume?|
|probably MTFB not being able to do a dual listing having an impact on sentiment but SLN dropped on such low volume I suspect there is nothing 'real' behind it|
|Any known reason for the drop this afternoon...|
|Interesting read gersemi - thank you.|